

**APPENDIX A - SPECIFICATION/CLAIM AMENDMENTS
INCLUDING NOTATIONS TO INDICATE CHANGES MADE**

Serial No.: 09/813.345

Docket No.: 180.00020102

Amendments to the following are indicated by underlining what has been added and bracketing what has been deleted. Additionally, all amendments have been shaded.

The paragraph beginning at page 3, line 27, has been amended as follows:

CGRP antagonists includes peptides from CGRP including amino acids 8-37 of β -CGRP (Park et al. *Am. J. Physiol.* 1989) having the amino acid sequence:

[REDACTED]

[REDACTED] (SEQ ID NO:1) and peptides from α -CGRP including amino acids 8-37 and having the amino acid sequence

[REDACTED]

[REDACTED] β -CGRP(8-37) [REDACTED] has been used to counteract the effects of CGRP. For example, CGRP(8-37) has been shown to reverse the hypotension and tachycardia produced by administration of LPS to rats (Huttemeir, et al. *Am. J. Physiol.* 265:H767-H769, 1993). In addition, CGRP(8-37) has some activity against amylin (Gardiner et al. *Diabetes* 40:948-951, 1991). The affinity for CGRP(8-37) varies between tissues. For example, data indicates that the affinity of CGRP(8-37) for mesenteric artery, kidney, heart and skeletal muscle is somewhat higher than the affinity of CGRP(8-37) for adipocytes and descending colon (Poyner, D. *Trends in Pharm. Sci.* 16:424-428, 1995).